A self-described leading Asset Manager in Healthcare

HBM Partners

HBM Healthcare Investments AG is a Switzerland-based venture capital company investing in emerging companies, mainly from the biotechnology and human medicine, diagnostics, as well as medical technology sectors. The Company focuses on unlisted companies, with two-thirds of assets being invested in private companies that offer high value-creation potential. As a holding company, it is involved in the acquisition, disposal and management of a diversified portfolio, as well as in financing and supporting the portfolio firms as a key partner. It focuses on companies with products either at an advanced stage of development or already available on the market. The primary investment areas are Western Europe and the United States. The Company's portfolio includes approximately 25 companies. As of March 31, 2012, the Company had six wholly owned subsidiaries, including three subsidiaries on Cayman Islands, two Barbados-based subsidiaries and a subsidiary in the United States.

Mineralys Therapeutics

Zosano Pharma

Nabriva Therapeutics

BioAtla

Galera Therapeutics

PTC Therapeutics

Pyxis Oncology

IVERIC bio

Acrivon Therapeutics

Ambrx

Aptinyx

Arcutis Biotherapeutics

Seer

Harmony Biosciences

Homology Medicines

Infinity Pharmaceuticals

Instil Bio

C4 Therapeutics

ChemoCentryx

IO Biotech

HBM Healthcare Investments AG

Morphic Therapeutic is a biotechnology company focused on the development of oral integrin therapeutics for the treatment of serious chronic diseases, including fibrosis.

Morphic Therapeutic

Pliant Therapeutics is a biotechnology company specializing in the discovery and development of novel therapies for fibrotic diseases.

Pliant Therapeutics

Avalo Therapeutics is a biotechnology company dedicated to developing therapies for fibrotic diseases and cancer.

Avalo Therapeutics

SAGE Therapeutics is a biopharmaceutical company focused on the development of novel medicines to treat life-altering central nervous system disorders.

SAGE Therapeutics

Dicerna Pharmaceuticals is a biopharmaceutical company focused on the development of RNA interference-based therapeutics for the treatment of rare diseases.

Dicerna Pharmaceuticals

Galecto, Inc. is a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer. The company's pipeline includes GB0139, an inhaled inhibitor of galectin-3 for the treatment of idiopathic pulmonary fibrosis and other pulmonary fibrosis diseases, and GB1211, an oral inhibitor of galectin-3 and LOXL2 for the treatment of myelofibrosis and other fibrotic diseases.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Jul 11, 2024 10:50 PM	c97efca9
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Jul 12, 2024 6:13 AM	babc975e
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	Jul 11, 2024 10:50 PM	02965ee1
translate crunchbase fundingrounds	general
peers	general	Jul 11, 2024 10:50 PM	1d4662a6
news basic	general	Jul 11, 2024 10:50 PM	de601a1f
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

HBMP

COM:HBMPARTNERS

HBM Partners